Muneaki Matsubara
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Muneaki Matsubara has a total of 95 co-authors. Here are the top co-authors by number of shared publications:
Nicole Piber
15 shared publicationsPeter Ewert
12 shared publications- Masamichi Ono
Department of Congenital and Pediatric Heart Surgery, TUM University Hospital, German Heart Center, Munich, Germany; Division of Congenital and Pediatric Heart Surgery, University Hospital of Munich, Ludwig- Maximilians-Universität München, Munich, Germany; Europäisches Kinderherzzentrum München , Munich 80636
11 shared publications - Alfred Hager
Department of Congenital Heart Disease and Pediatric Cardiology, German Heart Center Munich, University Hospital of Technische Universität München , Munich
10 shared publications Jürgen Hörer
Department of Congenital and Pediatric Heart Surgery, TUM University Hospital, German Heart Center, Munich, Germany
10 shared publicationsJonas Palm
Department of Congenital Heart Disease and Pediatric Cardiology, TUM University Hospital, German Heart Center, Munich, Germany
9 shared publications
Latest Publications
- Open Access
- 6 November 2026
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
Surgical outcomes of infective endocarditis in children and adults with congenital heart disease
- 6 November 2026
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
Open AccessSurgical outcomes of infective endocarditis in children and adults with congenital heart disease
- 15 October 2026
- Published by Springer Nature in Pediatric Cardiology
- p. 1-9
Clinical Outcome of Late Survivors Following the Classic Fontan Procedure
- 15 October 2026
- Published by Springer Nature in Pediatric Cardiology
- p. 1-9
Clinical Outcome of Late Survivors Following the Classic Fontan Procedure
- Open Access
- 14 August 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (9) , 5620-5625
Evaluating the efficacy of recombinant factor VIIa for non-surgical persistent bleeding in cardiovascular surgery: a retrospective cohort study
Background: Persistent bleeding after cardiovascular surgery challenges hemostatic management, especially in pediatric patients, but recombinant activated factor VIIa (rFVIIa), when used as a procoagulant, may improve patient outcomes. Materials and methods: We retrospectively evaluated 34 cardiac surgery patients who received recombinant rFVIIa for nonsurgical bleeding. Data on patient characteristics, surgical technique, rFVIIa administration, blood product use, complications, and hemostatic evaluation were collected. Red blood cell (RBC) transfusion volumes for 1 hour before and after rFVIIa administration were compared via a paired t -test. Results: Nineteen adult patients (mean age, 56.3 ± 15.3 years) and 15 pediatric patients [neonates (birth to 28 days), 7/15; infants (29 days to 1 year), 7/15; and preschoolers (3–6 years), 1/15] were included. RBC transfusion volumes were significantly reduced in adults (mean difference, 192.6 mL; 95% CI, 128.8–256.4 mL; P value < 0.001) and pediatric patients (mean difference, 37.0 mL/kg; 95% CI, 29.3–44.6 mL/kg; P value < 0.001) after rFVIIa. No thrombotic events were observed. Conclusion: The need for blood transfusion during complex and emergency cardiac surgery was significantly reduced with rFVIIa administration, which was judged effective in the management of bleeding during cardiac surgery. Large-scale trials are needed to optimize its use in cardiac surgery.
- 14 August 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (9) , 5620-5625
Open AccessEvaluating the efficacy of recombinant factor VIIa for non-surgical persistent bleeding in cardiovascular surgery: a retrospective cohort study
Background: Persistent bleeding after cardiovascular surgery challenges hemostatic management, especially in pediatric patients, but recombinant activated factor VIIa (rFVIIa), when used as a procoagulant, may improve patient outcomes. Materials and methods: We retrospectively evaluated 34 cardiac surgery patients who received recombinant rFVIIa for nonsurgical bleeding. Data on patient characteristics, surgical technique, rFVIIa administration, blood product use, complications, and hemostatic evaluation were collected. Red blood cell (RBC) transfusion volumes for 1 hour before and after rFVIIa administration were compared via a paired t -test. Results: Nineteen adult patients (mean age, 56.3 ± 15.3 years) and 15 pediatric patients [neonates (birth to 28 days), 7/15; infants (29 days to 1 year), 7/15; and preschoolers (3–6 years), 1/15] were included. RBC transfusion volumes were significantly reduced in adults (mean difference, 192.6 mL; 95% CI, 128.8–256.4 mL; P value < 0.001) and pediatric patients (mean difference, 37.0 mL/kg; 95% CI, 29.3–44.6 mL/kg; P value < 0.001) after rFVIIa. No thrombotic events were observed. Conclusion: The need for blood transfusion during complex and emergency cardiac surgery was significantly reduced with rFVIIa administration, which was judged effective in the management of bleeding during cardiac surgery. Large-scale trials are needed to optimize its use in cardiac surgery.
- Open Access
- 30 July 2026
- Published by Oxford University Press (OUP) in Interdisciplinary CardioVascular and Thoracic Surgery
- Vol. 41 (8)
Failing Fontan Following Total Cavopulmonary Connection: Extracardiac Biomarkers Reveal 2 Distinct Phenotypes With Divergent Clinical Courses
Objectives: Failing Fontan is an increasingly recognized complication after total cavopulmonary connection (TCPC), yet longitudinal biomarker data remain scarce. We aimed to characterize the incidence, biomarker trajectories, and prognostic determinants of failing Fontan. Methods: All patients who underwent primary TCPC (n = 650) or conversion to TCPC (n = 19) at our centre between 1994 and 2022 were reviewed. Lymphocyte count, N-terminal pro-brain natriuretic peptide (NT-proBNP) and its zlog value, and Fibrosis-4 index were assessed at 1 year before, 6 months before, at onset, and at last follow-up. Patients were classified into protein-losing enteropathy (PLE)/plastic bronchitis (PB) and heart failure phenotypes. Results: Failing Fontan developed in 78 primary TCPC patients (12.0%) and 12 conversion patients (63.2%). Conversion patients developed failing Fontan earlier (P < .001), but survival after onset was comparable. Lymphocyte counts declined before onset (2.49 to 0.89 × 10³/µL, P < .001) and the Fibrosis-4 index increased (0.060 to 0.330, P < .001). Phenotypes showed divergent profiles: zlog-NT-proBNP at onset was 0.71 in PLE/PB versus 5.34 in heart failure (P < .001). Lymphocytopenia (LP) predicted mortality early (hazard ratio 6.77, P = .013) but appeared protective at last follow-up (hazard ratio 0.18, P = .049), reflecting a phenotypic shift. On multivariable analysis, lower lymphocyte count independently predicted mortality (hazard ratio 2.44, P = .041), while stent implantation was independently associated with lower mortality (hazard ratio 0.32, P = .040). Conclusions: Lymphocyte counts and the Fibrosis-4 index change progressively before clinical onset and may serve as early warning biomarkers. The prognostic interpretation of LP depends on the underlying phenotype, underscoring the need for phenotype-aware monitoring.
- 30 July 2026
- Published by Oxford University Press (OUP) in Interdisciplinary CardioVascular and Thoracic Surgery
- Vol. 41 (8)
Open AccessFailing Fontan Following Total Cavopulmonary Connection: Extracardiac Biomarkers Reveal 2 Distinct Phenotypes With Divergent Clinical Courses
Objectives: Failing Fontan is an increasingly recognized complication after total cavopulmonary connection (TCPC), yet longitudinal biomarker data remain scarce. We aimed to characterize the incidence, biomarker trajectories, and prognostic determinants of failing Fontan. Methods: All patients who underwent primary TCPC (n = 650) or conversion to TCPC (n = 19) at our centre between 1994 and 2022 were reviewed. Lymphocyte count, N-terminal pro-brain natriuretic peptide (NT-proBNP) and its zlog value, and Fibrosis-4 index were assessed at 1 year before, 6 months before, at onset, and at last follow-up. Patients were classified into protein-losing enteropathy (PLE)/plastic bronchitis (PB) and heart failure phenotypes. Results: Failing Fontan developed in 78 primary TCPC patients (12.0%) and 12 conversion patients (63.2%). Conversion patients developed failing Fontan earlier (P < .001), but survival after onset was comparable. Lymphocyte counts declined before onset (2.49 to 0.89 × 10³/µL, P < .001) and the Fibrosis-4 index increased (0.060 to 0.330, P < .001). Phenotypes showed divergent profiles: zlog-NT-proBNP at onset was 0.71 in PLE/PB versus 5.34 in heart failure (P < .001). Lymphocytopenia (LP) predicted mortality early (hazard ratio 6.77, P = .013) but appeared protective at last follow-up (hazard ratio 0.18, P = .049), reflecting a phenotypic shift. On multivariable analysis, lower lymphocyte count independently predicted mortality (hazard ratio 2.44, P = .041), while stent implantation was independently associated with lower mortality (hazard ratio 0.32, P = .040). Conclusions: Lymphocyte counts and the Fibrosis-4 index change progressively before clinical onset and may serve as early warning biomarkers. The prognostic interpretation of LP depends on the underlying phenotype, underscoring the need for phenotype-aware monitoring.
- Open Access
- 27 July 2026
- Published by Cambridge University Press (CUP) in Cardiology in the Young
- Vol. 36 (8) , 1761
Serial changes of mitral and tricuspid valve diameter after the Norwood procedure in patients with aortic atresia – CORRIGENDUM
- 27 July 2026
- Published by Cambridge University Press (CUP) in Cardiology in the Young
- Vol. 36 (8) , 1761
Open AccessSerial changes of mitral and tricuspid valve diameter after the Norwood procedure in patients with aortic atresia – CORRIGENDUM
- 29 June 2026
- Published by Cambridge University Press (CUP) in Cardiology in the Young
- Vol. 36 (7) , 1-8
Impact of conotruncal anomalies on outcomes following total cavopulmonary connection
Objectives: The impact of conotruncal anomalies on long-term outcomes after total cavopulmonary connection remains unclear, particularly regarding haemodynamic performance and dominant ventricular morphology. Methods: All patients who underwent total cavopulmonary connection between 1994 and 2023 at a single centre were reviewed. Conotruncal anomalies were defined as transposition of the great arteries, double outlet right ventricle, tetralogy of Fallot, truncus arteriosus, and interrupted aortic arch type B. Four endpoints were analysed: transplant-free survival, Fontan failure, tachyarrhythmia, and ventricular dysfunction. Multivariable Cox regression, inverse probability of treatment weighting, and subgroup analyses were performed to disentangle conotruncal anomaly effects from dominant ventricular morphology. Results: Among the 650 patients, 291 (44.8%) were identified with conotruncal anomalies. During a median follow-up of 6.3 years, no differences were observed in transplant-free survival (log-rank p = 0.136) or Fontan failure ( p = 0.717) between groups. Dominant right ventricular morphology was independently associated with Fontan failure (hazard ratio: 2.20; p = 0.006) and tachyarrhythmia (hazard ratio: 3.22; p = 0.004). These findings were confirmed across all sensitivity analyses. No differences were detected in filling pressures, cardiac index, or peak oxygen uptake on post-operative catheterisation ( n = 226) and cardiopulmonary exercise testing ( n = 161). When stratified into four groups by conotruncal status and dominant ventricular morphology, freedom from Fontan failure clustered by morphology rather than diagnostic category (4-way log-rank p < 0.001). Conclusions: Conotruncal anomalies are not independently associated with adverse outcomes following total cavopulmonary connection. Dominant right ventricular morphology, not diagnostic category, is the principal determinant of long-term Fontan outcomes.
- 29 June 2026
- Published by Cambridge University Press (CUP) in Cardiology in the Young
- Vol. 36 (7) , 1-8
Impact of conotruncal anomalies on outcomes following total cavopulmonary connection
Objectives: The impact of conotruncal anomalies on long-term outcomes after total cavopulmonary connection remains unclear, particularly regarding haemodynamic performance and dominant ventricular morphology. Methods: All patients who underwent total cavopulmonary connection between 1994 and 2023 at a single centre were reviewed. Conotruncal anomalies were defined as transposition of the great arteries, double outlet right ventricle, tetralogy of Fallot, truncus arteriosus, and interrupted aortic arch type B. Four endpoints were analysed: transplant-free survival, Fontan failure, tachyarrhythmia, and ventricular dysfunction. Multivariable Cox regression, inverse probability of treatment weighting, and subgroup analyses were performed to disentangle conotruncal anomaly effects from dominant ventricular morphology. Results: Among the 650 patients, 291 (44.8%) were identified with conotruncal anomalies. During a median follow-up of 6.3 years, no differences were observed in transplant-free survival (log-rank p = 0.136) or Fontan failure ( p = 0.717) between groups. Dominant right ventricular morphology was independently associated with Fontan failure (hazard ratio: 2.20; p = 0.006) and tachyarrhythmia (hazard ratio: 3.22; p = 0.004). These findings were confirmed across all sensitivity analyses. No differences were detected in filling pressures, cardiac index, or peak oxygen uptake on post-operative catheterisation ( n = 226) and cardiopulmonary exercise testing ( n = 161). When stratified into four groups by conotruncal status and dominant ventricular morphology, freedom from Fontan failure clustered by morphology rather than diagnostic category (4-way log-rank p < 0.001). Conclusions: Conotruncal anomalies are not independently associated with adverse outcomes following total cavopulmonary connection. Dominant right ventricular morphology, not diagnostic category, is the principal determinant of long-term Fontan outcomes.
- 25 June 2026
- Published by Cambridge University Press (CUP) in Cardiology in the Young
- Vol. 36 (6) , 1227-1233
Serial changes of mitral and tricuspid valve diameter after the Norwood procedure in patients with aortic atresia
Background: In hypoplastic left heart syndrome with aortic atresia, the non-functional left ventricle may influence right ventricular performance. We evaluated serial changes in tricuspid and mitral valve diameters after the Norwood procedure and their relationship to right ventricular function. Methods: Of 150 patients who underwent the Norwood procedure (2001–2020), 47 died before total cavopulmonary connection. Of the 103 survivors, 76 with sufficient serial echocardiographic data were analysed (1,399 examinations). Tricuspid and mitral valve diameters were measured, and right ventricular function was assessed. Right ventricular dysfunction was defined as any degree of impairment. Mixed-effects models were used to account for repeated measures. Results: Median follow-up was 4.6 years (IQR 2.4–11.8). Right ventricular dysfunction was observed in 15.9% of examinations. Patients with right ventricular dysfunction had significantly larger tricuspid valve diameters than those with normal function (24.3 mm vs 23.4 mm, p = 0.006), whereas mitral valve diameters showed no significant difference (7.6 mm vs 7.1 mm, p = 0.120). The mitral/tricuspid ratio was similar between groups (0.320 versus 0.324, p = 0.340). Mixed-effects modelling showed that the tricuspid valve diameter remained 0.618 mm larger in the dysfunction group after adjusting for growth over time ( p = 0.029). Tricuspid valve diameter differences emerged at the bidirectional cavopulmonary shunt stage and accelerated through Fontan completion ( p < 0.001). Conclusions: In hypoplastic left heart syndrome with aortic atresia, right ventricular dysfunction is associated with progressive tricuspid valve enlargement but not with changes in the mitral/tricuspid ratio. While the stable ratio suggests proportional annular growth, a comprehensive volumetric assessment is needed to clarify ventricular-ventricular interactions.
- 25 June 2026
- Published by Cambridge University Press (CUP) in Cardiology in the Young
- Vol. 36 (6) , 1227-1233
Serial changes of mitral and tricuspid valve diameter after the Norwood procedure in patients with aortic atresia
Background: In hypoplastic left heart syndrome with aortic atresia, the non-functional left ventricle may influence right ventricular performance. We evaluated serial changes in tricuspid and mitral valve diameters after the Norwood procedure and their relationship to right ventricular function. Methods: Of 150 patients who underwent the Norwood procedure (2001–2020), 47 died before total cavopulmonary connection. Of the 103 survivors, 76 with sufficient serial echocardiographic data were analysed (1,399 examinations). Tricuspid and mitral valve diameters were measured, and right ventricular function was assessed. Right ventricular dysfunction was defined as any degree of impairment. Mixed-effects models were used to account for repeated measures. Results: Median follow-up was 4.6 years (IQR 2.4–11.8). Right ventricular dysfunction was observed in 15.9% of examinations. Patients with right ventricular dysfunction had significantly larger tricuspid valve diameters than those with normal function (24.3 mm vs 23.4 mm, p = 0.006), whereas mitral valve diameters showed no significant difference (7.6 mm vs 7.1 mm, p = 0.120). The mitral/tricuspid ratio was similar between groups (0.320 versus 0.324, p = 0.340). Mixed-effects modelling showed that the tricuspid valve diameter remained 0.618 mm larger in the dysfunction group after adjusting for growth over time ( p = 0.029). Tricuspid valve diameter differences emerged at the bidirectional cavopulmonary shunt stage and accelerated through Fontan completion ( p < 0.001). Conclusions: In hypoplastic left heart syndrome with aortic atresia, right ventricular dysfunction is associated with progressive tricuspid valve enlargement but not with changes in the mitral/tricuspid ratio. While the stable ratio suggests proportional annular growth, a comprehensive volumetric assessment is needed to clarify ventricular-ventricular interactions.
- Open Access
- 12 April 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (8) , 2930
Cross-Sectional Area Changes in the Total Cavopulmonary Connection Pathway and Its Impact on Liver Fibrosis
Background/Objectives: A known disadvantage of extracardiac Fontan is the absence of growth potential and potential late flow stagnation compared to lateral tunnel Fontan. This study investigates the differences in changes in the cross-sectional area and impact on liver fibrosis. Methods: The anteroposterior and lateral diameters of the Fontan pathways were measured using angiograms. Cross-sectional area and the indexed cross-sectional area were calculated, and their relation to Fibrosis-4 index was analyzed. Results: A total of 334 angiograms of 224 patients (212 extracardiac and 12 lateral tunnel Fontan) were evaluated. The median age at Fontan was 2.2 (Interquartile Range: 1.8–2.9) years. The median period from Fontan to angiogram was 3.3 (0.04–10.8) years. Cross-sectional areas remained unchanged in extracardiac Fontan patients and increased in lateral tunnel Fontan patients. The indexed cross-sectional areas in extracardiac Fontan patients decreased over time. The smallest indexed-cross-sectional areas were 200 mm2/m2 in extracardiac Fontan patients at 10 years postoperatively, whereas indexed cross-sectional areas in lateral tunnel Fontan patients were larger and more variable. Fibrosis-4 index increased time-dependently in both groups. Indexed cross-sectional area at the smallest level 2/m2 was identified as a risk factor for liver fibrosis. Conclusions: The Fontan pathway expanded in patients after lateral tunnel Fontan, whereas indexed cross-sectional area decreased over time after extracardiac Fontan. Importantly, in patients after extracardiac Fontan, narrowing of the Fontan pathway might be one of the risk factors for progression of liver fibrosis.
- 12 April 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (8) , 2930
Open AccessCross-Sectional Area Changes in the Total Cavopulmonary Connection Pathway and Its Impact on Liver Fibrosis
Background/Objectives: A known disadvantage of extracardiac Fontan is the absence of growth potential and potential late flow stagnation compared to lateral tunnel Fontan. This study investigates the differences in changes in the cross-sectional area and impact on liver fibrosis. Methods: The anteroposterior and lateral diameters of the Fontan pathways were measured using angiograms. Cross-sectional area and the indexed cross-sectional area were calculated, and their relation to Fibrosis-4 index was analyzed. Results: A total of 334 angiograms of 224 patients (212 extracardiac and 12 lateral tunnel Fontan) were evaluated. The median age at Fontan was 2.2 (Interquartile Range: 1.8–2.9) years. The median period from Fontan to angiogram was 3.3 (0.04–10.8) years. Cross-sectional areas remained unchanged in extracardiac Fontan patients and increased in lateral tunnel Fontan patients. The indexed cross-sectional areas in extracardiac Fontan patients decreased over time. The smallest indexed-cross-sectional areas were 200 mm2/m2 in extracardiac Fontan patients at 10 years postoperatively, whereas indexed cross-sectional areas in lateral tunnel Fontan patients were larger and more variable. Fibrosis-4 index increased time-dependently in both groups. Indexed cross-sectional area at the smallest level 2/m2 was identified as a risk factor for liver fibrosis. Conclusions: The Fontan pathway expanded in patients after lateral tunnel Fontan, whereas indexed cross-sectional area decreased over time after extracardiac Fontan. Importantly, in patients after extracardiac Fontan, narrowing of the Fontan pathway might be one of the risk factors for progression of liver fibrosis.
- Open Access
- 18 March 2026
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 122 (3) , 680-689
Mechanical Atrioventricular Valve Replacement During and After the Single-Ventricle Palliation
- 18 March 2026
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 122 (3) , 680-689
Open AccessMechanical Atrioventricular Valve Replacement During and After the Single-Ventricle Palliation